-
Nanobiotix S.A. (NBTX $21.63)
- $21.63 Cap: $951M
- View NBTX Profile
- View Questions on NBTX
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
Almonty Industries Inc. (AII $12.33)
- $12.33 Cap: $2.81B
- View AII Profile
- View Questions on AII
-
Nanobiotix S.A. (NBTX $21.63)
- $21.63 Cap: $951M
- View NBTX Profile
- View Questions on NBTX
-
Terns Pharmaceuticals Inc. (TERN $36.97)
- $36.97 Cap: $3.68B
- View TERN Profile
- View Questions on TERN
-
Resolute Holdings Management (RHLD $219.25)
- $219.25 Cap: $1.78B
- View RHLD Profile
- View Questions on RHLD
Q: Hi team,
Do you find anything worth buying now for growth, in these stars of 2025 ?
Resolute Holdings rhld-n Terns Pharma tern-q Celcuity celc-q Nanobiotix nbtx-q Cidara Therapeutics cdtx-q Palvella Therapeutics pvla-q Almonty Industries alm-q Hycroft Mining hymc-q Abivax abvx-q Regencell Bio rgc-Q
In which order would you buy ?
Gratefully,
Jacques IDS
Do you find anything worth buying now for growth, in these stars of 2025 ?
Resolute Holdings rhld-n Terns Pharma tern-q Celcuity celc-q Nanobiotix nbtx-q Cidara Therapeutics cdtx-q Palvella Therapeutics pvla-q Almonty Industries alm-q Hycroft Mining hymc-q Abivax abvx-q Regencell Bio rgc-Q
In which order would you buy ?
Gratefully,
Jacques IDS
Insiders
Share Information
SEC Filings
News and Media